

06/12/2010

***National Institute for  
Health and Clinical Excellence***

Level 1A, City Tower  
Piccadilly Plaza  
Manchester  
M1 4BD

Tel: 0845 003 7780  
Fax: 0845 003 7784

[www.nice.org.uk](http://www.nice.org.uk)

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Single Technology Appraisal (STA)**

**Everolimus for the second-line treatment of metastatic renal cell carcinoma**

Dear Karen

Re: Your request for further information about the adjustments made by the ERG to the Novartis probabilistic model (see email below).

The mean output of £51,661 per QALY gained (from scenario A) was derived from the probabilistic analysis with the model run for 1000 iterations rather than 100. No specific or additional alterations were made to the parameters of the model as presented by Novartis.

Attached is the original ERG analysis report for reference (you will already have a copy of this with the evaluation report).

If you have any further queries or require additional information please contact (insert name).

Best regards  
Rebecca

**Rebecca Pye**

Technology Appraisals Administrator - Committee C  
National Institute for Health and Clinical Excellence  
Level 1A | City Tower | Piccadilly Plaza | Manchester M1 4BD | United Kingdom  
Tel: 44 (0)161 219 3851 | Fax: 44 (0)207 061 9806  
Web: <http://nice.org.uk>

.....  
From:  
Sent: 23 November 2010 10:26  
To: Rebecca Pye  
Cc: Lori Farrar; Frances Sutcliffe; Rebecca Trowman  
Subject: Re: FAD to consultees: Renal cell carcinoma (second line

**Appendix 3 - Email sent from Novartis on 23.11.10 and Response Dated 6.12.10**

metastatic) - everolimus  
Importance: High

Dear Rebecca

Please could we request a copy of the adjustments made by PenTAG to our probabilistic model to generate the probabilistic mean ICER of £51.7k/QALY. although we have a copy of the report entitled, "Everolimus response to Additional Sensitivity Analyses" it is not absolutely clear how PenTAG have made the adjustments. It would therefore be valuable for us to have a copy of the adjusted model at you earliest convenience in order to understand exactly how the £51.7k/QALY was derived.

Many thanks,

Kind regards

Karen

The information contained in this message and any attachments is intended for the addressee(s) only. If you are not the addressee, you may not disclose, reproduce or distribute this message. If you have received this message in error, please advise the sender and delete it from your system. Any personal data sent in reply to this message will be used in accordance with provisions of the Data Protection Act 1998 and only for the purposes of the Institute's work.

All messages sent by NICE are checked for viruses, but we recommend that you carry out your own checks on any attachment to this message. We cannot accept liability for any loss or damage caused by software viruses.

<http://www.nice.org.uk>